Immune-Checkpoint-Inhibitor Therapy—Principles and Relevance of Biomarkers for Pathologists and Oncologists
- 3 October 2022
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Advances in Anatomic Pathology
- Vol. Publish Ah (3), 160-166
- https://doi.org/10.1097/pap.0000000000000373
Abstract
Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning.Keywords
This publication has 46 references indexed in Scilit:
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 2018
- Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patientsPLOS ONE, 2017
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung CancerCancer Discovery, 2017
- The “cancer immunogram”Science, 2016
- Targeting the Heterogeneity of Cancer with Individualized Neoepitope VaccinesClinical Cancer Research, 2016
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 2016
- PD-L1 and Survival in Solid Tumors: A Meta-AnalysisPLOS ONE, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Signatures of mutational processes in human cancerNature, 2013
- Melanoma drug wins US approvalNature, 2011